
Novartis to Boost US Flu Vaccine Supply, Gains Access to Intercell's Technology
Novartis Vaccines (Basel, Switzerland, www.novartisvaccines.com) plans to produce approximately 40 million doses of its Fluvirin vaccine for distribution in the US during the upcoming 2007–2008 influenza season-a 30% increase in supply from Novartis compared with the previous influenza season.
Novartis Vaccines (Basel, Switzerland,
Novartis has also formed a strategic alliance with Intercell AG (Vienna, Austria,
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.